This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

https://gskpro-com-preprod-cf5.gdsgsk.com/en-us/products/nucala/about/,1000

hyperlink,10000

CHOOSE NUCALA FOR REAL-LIFE RESULTS

NUCALA is indicated for the add-on maintenance treatment of patients 6 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

proven protection

53% reduction in exacerbations vs placebo1*

real-world evidence

Associated with:

69% reduction in exacerbations from baseline2

34% of patients eliminated maintenance OCS use2

Results are descriptive

long-term results

The only anti-interleukin 5 (IL-5) with a

4.5-year

open-label study that evaluated safety and efficacy3

  •   REALITI-A2:  Interim analysis of a prospective observational cohort study of 368 patients. Exacerbations: 4.63/year at baseline vs 1.43/year at 12 months. OCS: 34% (43/125) during Weeks 53-56 of patients on maintenance OCS at baseline. Results are descriptive. Study Limitations: May not reflect final results. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: lack of comparator arm; differences in patient populations and data collection vs randomized controlled trials.
  •   *MENSA1: 32-week placebo-controlled study in 576 patients. NUCALA: 0.83/year, placebo: 1.74/year; P<0.001.
  •   ‡Following the optimization phase in a controlled OCS reduction trial, 14% (10/69) of patients treated with NUCALA vs 8% (5/66) treated with placebo eliminated daily OCS use while maintaining asthma control (See Clinical Efficacy).5

REFERENCES:

  1. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
  2. Data on file, GSK.
  3. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751.
  4. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.
  5. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-1197.